FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065655717> ?p ?o ?g. }

• W2065655717 endingPage "384.e1" @default.
• W2065655717 startingPage "377" @default.
• W2065655717 abstract "Background & Aimsn-3 polyunsaturated fatty acids reduce insulin resistance, lipogenesis, and inflammation, which are features of nonalcoholic steatohepatitis (NASH). Ethyl-eicosapentanoic acid (EPA-E) is a synthetic polyunsaturated fatty acid that reduces hypertriglyceridemia. We report the final results of a phase 2b multicenter, prospective, double-blind, randomized, placebo-controlled trial of EPA-E for NASH.MethodsOur study, performed at 37 sites in North America, included subjects with NASH and nonalcoholic fatty liver disease (NAFLD) activity scores ≥4, with minimum scores of 1 for steatosis and inflammation, along with either ballooning or at least stage 1a fibrosis. A total of 243 subjects were randomly assigned to groups given placebo (n = 75), low-dosage EPA-E (1800 mg/d; n = 82), or high-dosage EPA-E (2700 mg/d; n = 86) for 12 months. Subjects were examined at 4-week intervals for 3 months, 6-week intervals for the next 3 months, and every 3 months thereafter, until 1 month after the last dose was taken. Liver biopsies were collected 2 weeks after the last dose of EPA-E or placebo. The primary efficacy end point was NAFLD activity score ≤3, without worsening of fibrosis; or a decrease in NAFLD activity score by ≥2 with contribution from >1 parameter, without worsening of fibrosis, 1 year after the last dose of EPA-E or placebo was given.ResultsSimilar proportions of subjects in each group met the primary end point (40%, 37%, and 35.9% for placebo, low-dosage, and high-dosage EPA-E, respectively). EPA-E had no significant effects on steatosis, inflammation, ballooning, or fibrosis scores. There were no significant effects on levels of liver enzymes, insulin resistance, adiponectin, keratin 18, high-sensitivity C-reactive protein, or hyaluronic acid. High-dosage EPA-E reduced levels of triglyceride (−6.5 mg/dL vs an increase of 12 mg/dL in the placebo group; P = .03). There were no treatment-related serious adverse events.ConclusionsIn a phase 2 trial, EPA-E had no significant effect on the histologic features of NASH. EPA-E reduced subjects’ levels of triglyceride compared with placebo, without any increase in serious adverse events. Clinicaltrials.gov Number: 01154985. n-3 polyunsaturated fatty acids reduce insulin resistance, lipogenesis, and inflammation, which are features of nonalcoholic steatohepatitis (NASH). Ethyl-eicosapentanoic acid (EPA-E) is a synthetic polyunsaturated fatty acid that reduces hypertriglyceridemia. We report the final results of a phase 2b multicenter, prospective, double-blind, randomized, placebo-controlled trial of EPA-E for NASH. Our study, performed at 37 sites in North America, included subjects with NASH and nonalcoholic fatty liver disease (NAFLD) activity scores ≥4, with minimum scores of 1 for steatosis and inflammation, along with either ballooning or at least stage 1a fibrosis. A total of 243 subjects were randomly assigned to groups given placebo (n = 75), low-dosage EPA-E (1800 mg/d; n = 82), or high-dosage EPA-E (2700 mg/d; n = 86) for 12 months. Subjects were examined at 4-week intervals for 3 months, 6-week intervals for the next 3 months, and every 3 months thereafter, until 1 month after the last dose was taken. Liver biopsies were collected 2 weeks after the last dose of EPA-E or placebo. The primary efficacy end point was NAFLD activity score ≤3, without worsening of fibrosis; or a decrease in NAFLD activity score by ≥2 with contribution from >1 parameter, without worsening of fibrosis, 1 year after the last dose of EPA-E or placebo was given. Similar proportions of subjects in each group met the primary end point (40%, 37%, and 35.9% for placebo, low-dosage, and high-dosage EPA-E, respectively). EPA-E had no significant effects on steatosis, inflammation, ballooning, or fibrosis scores. There were no significant effects on levels of liver enzymes, insulin resistance, adiponectin, keratin 18, high-sensitivity C-reactive protein, or hyaluronic acid. High-dosage EPA-E reduced levels of triglyceride (−6.5 mg/dL vs an increase of 12 mg/dL in the placebo group; P = .03). There were no treatment-related serious adverse events. In a phase 2 trial, EPA-E had no significant effect on the histologic features of NASH. EPA-E reduced subjects’ levels of triglyceride compared with placebo, without any increase in serious adverse events. Clinicaltrials.gov Number: 01154985." @default.
• W2065655717 created "2016-06-24" @default.
• W2065655717 creator A5012831120 @default.
• W2065655717 creator A5047141065 @default.
• W2065655717 creator A5054228197 @default.
• W2065655717 creator A5070639714 @default.
• W2065655717 creator A5086610543 @default.
• W2065655717 date "2014-08-01" @default.
• W2065655717 modified "2023-10-04" @default.
• W2065655717 title "No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial" @default.
• W2065655717 cites W1969295126 @default.
• W2065655717 cites W1975567145 @default.
• W2065655717 cites W1985850536 @default.
• W2065655717 cites W2001837599 @default.
• W2065655717 cites W2012257654 @default.
• W2065655717 cites W2030532669 @default.
• W2065655717 cites W2030666214 @default.
• W2065655717 cites W2051648756 @default.
• W2065655717 cites W2059700860 @default.
• W2065655717 cites W2062812115 @default.
• W2065655717 cites W2066810845 @default.
• W2065655717 cites W2067681932 @default.
• W2065655717 cites W2067740038 @default.
• W2065655717 cites W2070407599 @default.
• W2065655717 cites W2084776235 @default.
• W2065655717 cites W2087011218 @default.
• W2065655717 cites W2089535377 @default.
• W2065655717 cites W2093824918 @default.
• W2065655717 cites W2098555833 @default.
• W2065655717 cites W2102656403 @default.
• W2065655717 cites W2106931931 @default.
• W2065655717 cites W2139112405 @default.
• W2065655717 cites W2156116850 @default.
• W2065655717 cites W2168807236 @default.
• W2065655717 cites W2270175496 @default.
• W2065655717 cites W32111248 @default.
• W2065655717 doi "https://doi.org/10.1053/j.gastro.2014.04.046" @default.
• W2065655717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24818764" @default.
• W2065655717 hasPublicationYear "2014" @default.
• W2065655717 type Work @default.
• W2065655717 sameAs 2065655717 @default.
• W2065655717 citedByCount "248" @default.
• W2065655717 countsByYear W20656557172014 @default.
• W2065655717 countsByYear W20656557172015 @default.
• W2065655717 countsByYear W20656557172016 @default.
• W2065655717 countsByYear W20656557172017 @default.
• W2065655717 countsByYear W20656557172018 @default.
• W2065655717 countsByYear W20656557172019 @default.
• W2065655717 countsByYear W20656557172020 @default.
• W2065655717 countsByYear W20656557172021 @default.
• W2065655717 countsByYear W20656557172022 @default.
• W2065655717 countsByYear W20656557172023 @default.
• W2065655717 crossrefType "journal-article" @default.
• W2065655717 hasAuthorship W2065655717A5012831120 @default.
• W2065655717 hasAuthorship W2065655717A5047141065 @default.
• W2065655717 hasAuthorship W2065655717A5054228197 @default.
• W2065655717 hasAuthorship W2065655717A5070639714 @default.
• W2065655717 hasAuthorship W2065655717A5086610543 @default.
• W2065655717 hasBestOaLocation W20656557171 @default.
• W2065655717 hasConcept C126322002 @default.
• W2065655717 hasConcept C134018914 @default.
• W2065655717 hasConcept C141359234 @default.
• W2065655717 hasConcept C142724271 @default.
• W2065655717 hasConcept C168563851 @default.
• W2065655717 hasConcept C171089720 @default.
• W2065655717 hasConcept C19038510 @default.
• W2065655717 hasConcept C203092338 @default.
• W2065655717 hasConcept C204787440 @default.
• W2065655717 hasConcept C27081682 @default.
• W2065655717 hasConcept C2776175330 @default.
• W2065655717 hasConcept C2776919658 @default.
• W2065655717 hasConcept C2776954865 @default.
• W2065655717 hasConcept C2778163477 @default.
• W2065655717 hasConcept C2778772119 @default.
• W2065655717 hasConcept C2778913445 @default.
• W2065655717 hasConcept C2779134260 @default.
• W2065655717 hasConcept C2779478299 @default.
• W2065655717 hasConcept C2780559512 @default.
• W2065655717 hasConcept C3018708256 @default.
• W2065655717 hasConcept C543025807 @default.
• W2065655717 hasConcept C55493867 @default.
• W2065655717 hasConcept C71924100 @default.
• W2065655717 hasConcept C86803240 @default.
• W2065655717 hasConcept C90924648 @default.
• W2065655717 hasConceptScore W2065655717C126322002 @default.
• W2065655717 hasConceptScore W2065655717C134018914 @default.
• W2065655717 hasConceptScore W2065655717C141359234 @default.
• W2065655717 hasConceptScore W2065655717C142724271 @default.
• W2065655717 hasConceptScore W2065655717C168563851 @default.
• W2065655717 hasConceptScore W2065655717C171089720 @default.
• W2065655717 hasConceptScore W2065655717C19038510 @default.
• W2065655717 hasConceptScore W2065655717C203092338 @default.
• W2065655717 hasConceptScore W2065655717C204787440 @default.
• W2065655717 hasConceptScore W2065655717C27081682 @default.
• W2065655717 hasConceptScore W2065655717C2776175330 @default.
• W2065655717 hasConceptScore W2065655717C2776919658 @default.
• W2065655717 hasConceptScore W2065655717C2776954865 @default.
• W2065655717 hasConceptScore W2065655717C2778163477 @default.

• next